Ranking Profile - Affimed NV

Introduction

Affimed NV (Affimed), is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. It develops pipeline products for the treatment of cancers. The pipleline products includes AFM13, AFM24, AFM28. AFM13 is a first of its kind ICE that is intended to treat certain CD30-positive (CD30+) cancers, such as Hodgkin lymphoma and other types of lymphomas. AFM24 is an epidermal growth factor receptor. AFM24 was developed to address limitations of current therapeutic anti-EGFR monoclonal antibodies, such as treatment resistance or toxicities. The company develops products from the proprietary fit-for-purpose ROCK platform. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.